Sermorelin injections are a prescription, compounded form of sermorelin acetate, a lab-made version of the hormone that tells the pituitary gland to release growth hormone. They are not FDA-approved. A legitimate prescription follows one chain: an intake, review by an independent licensed clinician, a prescription only if appropriate, preparation by a licensed pharmacy, and follow-up led by your clinician. This guide walks through each step without dosing.

Key takeaways

What are sermorelin injections?

Sermorelin injections are a compounded, prescription-only injectable form of sermorelin acetate. Sermorelin works upstream of growth hormone: it signals the pituitary to release the body's own growth hormone rather than supplying growth hormone itself.

Sermorelin is a GHRH analog. GHRH (growth-hormone-releasing hormone) is a natural hormone made in the hypothalamus, a region at the base of the brain. An analog is a lab-made molecule built to mimic a natural one. The pituitary, a small gland just below the hypothalamus, responds to GHRH by releasing growth hormone.

The original brand product, Geref, was studied in two ways: to help diagnose growth hormone deficiency in children, and to treat certain children with that deficiency (BioDrugs, 1999). That brand is gone. The sermorelin injections prescribed in the US today are compounded, meaning a licensed compounding pharmacy or outsourcing facility prepares them rather than a manufacturer producing an FDA-approved product.

Sermorelin is also not HGH (human growth hormone). HGH is the hormone itself; sermorelin is a signal that asks the body to make its own. The mechanism and legal differences are covered in Sermorelin vs HGH: mechanism, law and evidence.

Is sermorelin FDA-approved?

No. No sermorelin product currently holds FDA approval. Brand Geref was FDA-approved and later discontinued, and today's compounded sermorelin is not FDA-approved (FDA, 2025).

Geref's approval-era evidence was pediatric: a published review covers sermorelin's use in diagnosing and treating idiopathic growth hormone deficiency (deficiency with no identified cause) in children (BioDrugs, 1999). That review's scope was children, so it does not establish anything about adults, aging, weight loss, muscle, sleep or recovery. Geref's approval never extended to any compounded version.

Compounded is also not the same as generic. A generic drug is FDA-approved and must show therapeutic equivalence to a brand, while a compounded drug is not approved by FDA at all (FDA, 2025). FDA does not review compounded drugs for safety or effectiveness before they are marketed, and it has seen some compounders make misleading statements suggesting their products met the standard for FDA approval (FDA, 2026). If a seller implies otherwise, treat that as a warning sign.

How sermorelin injections are prescribed and dispensed

A legitimate sermorelin prescription passes through two sets of hands: an independent licensed clinician who decides whether it's appropriate, and a licensed pharmacy that prepares and dispenses it. Neither step should be a formality.

  1. Intake. You complete a structured health questionnaire covering your history, current medications and supplements, and goals.
  2. Clinical review. An independent licensed clinician reviews your intake. Some treatments or states may require a live visit. Consultation timing varies by clinician availability.
  3. Decision. A prescription is written only if appropriate. Not everyone qualifies. Eligibility depends on your intake and clinical review, and that's how it should work.
  4. Preparation. If prescribed, a licensed pharmacy compounds the medication.
  5. Dispensing. The pharmacy labels it for you and ships or hands it over with instructions.
  6. Follow-up. Your clinician decides what check-ins are appropriate.

The review is a real decision for a reason. FDA's position is that compounded drugs should be used only in patients whose medical needs can't be met by an FDA-approved drug, and that unnecessary use can expose patients to serious health risks (FDA, 2025).

RoleWhoResponsible for
DecideIndependent licensed clinicianWhether sermorelin is appropriate, the prescription, follow-up
PrepareLicensed 503A pharmacy or 503B outsourcing facilityCompounding to the prescription and labeling it
InstructPharmacy label and pharmacist, plus your clinicianHow to store and handle your specific preparation

Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities. The numbers refer to sections of federal law. Drugs made in outsourcing facilities are subject to CGMP (current good manufacturing practice) requirements, a set of quality rules for how drugs are made (FDA, 2025). Pharmacy quality matters because poor compounding practices can cause contamination or a medication without the strength, quality and purity it should have, which can lead to serious injury and death (FDA, 2026).

When a prescription arrives, check that it includes:

If anything doesn't match, contact the pharmacy before using it. Vials sold online as "research use only" skip every step above; the difference is covered in prescription sermorelin vs research vials.

Where do sermorelin handling instructions come from?

They come from the pharmacy that dispensed your medication and the clinician who prescribed it. The label, any pharmacy insert and pharmacist counseling, together with your clinician's guidance, are the instructions that apply to your preparation.

This article gives no dosing, mixing, timing or injection steps on purpose. Strength, form and storage needs can differ from one compounded preparation to another. Compounded sermorelin also has no current FDA label, so a dosing chart online isn't drawn from official prescribing information that applies to what you were dispensed. A chart can look precise and still not match your vial.

If you're unsure about any step, ask the pharmacist or your clinician. Don't substitute instructions from forums, dosing calculators or other people's "protocols."

What monitoring looks like during sermorelin therapy

No current FDA label sets a monitoring schedule for compounded sermorelin, so follow-up, including whether any lab work is needed, is your clinician's decision. Ask what it will look like before you start.

In general, follow-up in clinician-guided care covers how you're doing, any side effects, new diagnoses, and any new medications or supplements. Lab work happens only if your clinician decides it's useful. You may hear about IGF-1 (insulin-like growth factor 1), a blood marker that reflects growth hormone activity. Whether to test it, and how to read the result, is a clinical judgment.

Report side effects and anything unexpected to your clinician. Questions about the medication itself, such as storage or the label, go to the pharmacy. Because FDA doesn't review compounded drugs before they reach patients (FDA, 2026), reports from patients and clinicians help problems surface. You or your clinician can also report suspected side effects to FDA's MedWatch program.

Questions to ask before starting:

  1. What will follow-up look like, and who starts it?
  2. How do I reach a clinician between check-ins?
  3. Which questions go to the pharmacy, and which go to my clinician?
  4. What would make you recommend stopping or changing course?

Clinician-guided telehealth is not for emergencies. If you have a severe or urgent reaction, call 911 or go to the nearest emergency room.

What the evidence shows, and its limits

The published evidence on sermorelin is older, limited and mostly pediatric. The case for adult "age-management" use rests largely on commentary rather than large randomized trials.

SourceTypeWhat it coversWhat it can't show
Prakash and Goa, BioDrugs (1999)Narrative reviewDiagnosis and treatment of children with idiopathic GHDAdult outcomes
Drugs & Therapy Perspectives (1999)Drug-evaluation summarySermorelin compared with somatropin for pediatric useAdult use
Walker, Clinical Interventions in Aging (2006)Opinion commentaryAn argument for sermorelin in adult-onset GH insufficiencyAny outcome
Scientific Reports (2024)Systematic review and network meta-analysisLong-acting growth hormone in childrenAnything about sermorelin directly

The approval-era evidence was pediatric. Prakash and Goa's narrative review covered sermorelin's use in diagnosing and treating children with idiopathic growth hormone deficiency (BioDrugs, 1999). A drug-evaluation summary the same year, titled "Sermorelin: No Sizable Gains Over Somatropin," concluded it offered no sizable gains over recombinant growth hormone for that pediatric use (Drugs & Therapy Perspectives, 1999).

For childhood growth hormone deficiency today, a 2024 systematic review notes that Growth Hormone Research Society consensus guidelines recommend recombinant human growth hormone (Scientific Reports, 2024). That review studied growth hormone products, not sermorelin.

The adult argument is best represented by Walker's two-page commentary, which proposes that sermorelin may be a better approach than recombinant growth hormone for adult-onset growth hormone insufficiency (Clinical Interventions in Aging, 2006). It is an opinion piece, not a trial, so it cannot establish what sermorelin does for adults. For a graded summary, see the sermorelin evidence summary.

Who should not use sermorelin, or should check first

Sermorelin through clinician-guided telehealth isn't for anyone under 21, anyone who needs emergency care, or as a home solution for a child's growth concerns. For other adults, the deciding factors are a complete intake and the independent licensed clinician's judgment.

A child's growth problem belongs with a pediatric specialist, and current consensus guidance points to recombinant growth hormone for childhood deficiency (Scientific Reports, 2024).

For adults, disclose these fully at intake. This isn't an official contraindication list. It's the information a clinician needs to make a sound decision:

Sermorelin also isn't a fit for anyone unwilling to use a prescription from a licensed pharmacy or to take part in follow-up. Clinician-guided care depends on both.

How access works through New Blue

New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.

The sermorelin pathway starts with an asynchronous intake, a structured questionnaire you complete on your own schedule, which an independent licensed clinician reviews. Some treatments or states may require a live visit. Consultation timing varies by clinician availability. If prescribed, a licensed partner pharmacy ships the medication directly to you. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities, and this compounded injectable is not FDA-approved.

New Blue is LegitScript certified. Availability varies by state, so check state availability first.

If you're not prescribed after the online review, all of what you paid comes back. If your state needs a video visit, everything except the cost of that visit comes back. Details are in the refund policy. For current pricing and pathway details, see the sermorelin treatment page.

Frequently Asked Questions

Are sermorelin injections FDA-approved?

No. The brand product, Geref, was FDA-approved and later discontinued, and its approval-era evidence was pediatric. The sermorelin injections prescribed today are compounded, and compounded medications are not FDA-approved.

Is compounded sermorelin a generic version of Geref?

No. A generic drug is FDA-approved and must show therapeutic equivalence to a brand product. Compounded sermorelin is prepared by a state-licensed 503A compounding pharmacy or an FDA-registered 503B outsourcing facility and is not FDA-approved.

Do I need a prescription for sermorelin injections?

Yes. A legitimate prescription starts with a health intake that an independent licensed clinician reviews, and some treatments or states may require a live visit. A prescription is written only if appropriate, and not everyone qualifies.

Who tells me how to store and use my sermorelin?

The dispensing pharmacy and your prescribing clinician do. The pharmacy label, any insert and pharmacist counseling apply to your specific preparation, along with your clinician's guidance. Online dosing charts and forum protocols may not match what was dispensed to you.

What monitoring will my clinician do?

Your clinician sets it, because no current FDA label defines a monitoring schedule for compounded sermorelin. Follow-up usually covers how you're doing, side effects and medication changes, with lab work only if your clinician decides it's useful. Ask before starting what follow-up will look like and how to reach a clinician between check-ins.

Can I get sermorelin in my state?

Availability varies by state. You can check yours on the state availability page before starting an intake.

What happens if I'm not prescribed?

If you're not prescribed after the online review, all of what you paid comes back. If your state needs a video visit, everything except the cost of that visit comes back. The full terms are in the refund policy.

Sources

  1. Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  2. Consumer and Health Care Professional Information (Human Drug Compounding). U.S. Food and Drug Administration, 2026. https://www.fda.gov/drugs/human-drug-compounding/consumer-and-health-care-professional-information
  3. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 1999. https://pubmed.ncbi.nlm.nih.gov/18031173/
  4. Sermorelin: No Sizable Gains Over Somatropin. Drugs & Therapy Perspectives, 1999. https://doi.org/10.2165/00042310-199914120-00001
  5. Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 2006. https://doi.org/10.2147/CIIA.2006.1.4.307
  6. Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis. Scientific Reports, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10997584/

Medical disclaimer: This article is for educational purposes only and is not medical advice. Treatment decisions, including whether any medication is appropriate for you, are made by an independent licensed clinician based on your intake and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider.

Related treatment guide

Related reading

Content review & editorial standards

This page is educational content from the New Blue Health Editorial Team. It is checked under the New Blue Health Content Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.

Start Your Visit